WO1995003331A1 - Human mhc class ii double transgene and uses - Google Patents

Human mhc class ii double transgene and uses Download PDF

Info

Publication number
WO1995003331A1
WO1995003331A1 PCT/GB1994/001582 GB9401582W WO9503331A1 WO 1995003331 A1 WO1995003331 A1 WO 1995003331A1 GB 9401582 W GB9401582 W GB 9401582W WO 9503331 A1 WO9503331 A1 WO 9503331A1
Authority
WO
WIPO (PCT)
Prior art keywords
human
transgene
hla
dr4dw4
beta
Prior art date
Application number
PCT/GB1994/001582
Other languages
English (en)
French (fr)
Inventor
Joanne Lesley Whittaker
John Edward Norris Morten
Original Assignee
Zeneca Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zeneca Limited filed Critical Zeneca Limited
Priority to JP7505017A priority Critical patent/JPH09501315A/ja
Priority to AU72314/94A priority patent/AU7231494A/en
Priority to EP94921706A priority patent/EP0710250A1/en
Publication of WO1995003331A1 publication Critical patent/WO1995003331A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0381—Animal model for diseases of the hematopoietic system

Definitions

  • HHC Hajor histocompatibility complex
  • HHC restriction and antigen presentation are cell surface heterodimeric glycoproteins composed of 34 kilodalton ⁇ - and 29 kilodalton ⁇ -chains. These proteins play a crucial role in the immunological processes of self-tolerance, HHC restriction and antigen presentation. Each of these processes involves the interaction of HHC molecules with antigen, T cell ⁇ - ⁇ receptors (TCRs) and accessory molecules such as CD4. The relationship between these interactions and the biology of tolerance induction and HHC-restricted antigen presentation is, as yet, not fully understood.
  • HHC and TCR gene products are characterised by extensive structural complexity (Natural History of the Major Histocompatibility Complex, 1986, J. Klein - Viley & Sons). An important functional consequence of this complexity is diversity in antigen recognition. In the evolution of independent mammalian species, MHC and TCR complexes have diverged significantly in gene structure, number and regulation.
  • transgenic DR ⁇ -E ⁇ mice Such mice express the human DR ⁇ gene with no apparent modulation of immune function.
  • Nishimura et al J. Immunology, 1990, JL45, 353-360 describe a line of transgenic HLA-DQw6 mice.
  • a mixture of DQw6A and DQw6B DNA was injected into 40 fertilised eggs from C57BL/6 mice.
  • Four neonate pups were obtained out of which one mouse carried both the DQw6A and DQw6B genes.
  • MHC class II double transgenes there have been no further reports of these.
  • transgenic non-human mammal which is ⁇ , ⁇ -double transgenic for an MHC class II HLA-DR gene complex.
  • MHC class II H A-DR gene complexes include those disclosed by Kappes and Strominger in Ann. Rev. Biochem., 1988, 57, 991-1028; Harsh and Bodmer in "Gene Registry, HLA class II nucleotide sequences, 1991”; Lanchbury in Clinical and Experimental Perspectives in Cyclosporin Therapy, 1992, 1_ (1), 15-17; Wordsworth et al in Am. J. Hum. Genet., 1992, 51 ⁇ , 585-591 and P.N.A.S., 1989, 8_6, 10049-10053.
  • Such complexes include DR1, DRwlO and DR4 subtypes including DR4Dw4, DR4Dwl3, DR4Dwl4.1, DR4Dw 14.2 and DR4Dwl5.
  • a particular complex is DR4Dwl4.
  • a further particular complex is the human HLA-DR4Dw4- ⁇ , ⁇ complex.
  • the mammal is any convenient non-human mammal, for example as used in laboratory test procedures, such as rodents for example mice or rats, more conveniently mice.
  • the transgenic non-human mammal of the invention may be either heterozygous or homozygous for the desired ⁇ , ⁇ -tr-insgene, but is conveniently homozygous.
  • a preferred non-human mammal of the invention is a mouse transgenic for the human H A-DR4Dw4- ⁇ , ⁇ complex, find preferably homozygous for the ⁇ and ⁇ transgenes.
  • the transgenic non-human mammal of the invention is conveniently obtained by mating appropriate individual non-human mammals who are ⁇ - transgenic and ⁇ -transgenic respectively for the desired MHC class II DR gene complex. Conventional mating and breeding procedures may be employed.
  • the desired double transgenic progeny are preferably back-crossed into a background strain which does not have any significant deletion in either the ⁇ - or ⁇ - gene. This is to minimise any unwanted human/non-human gene pairings and to promote reliable expression of the desired human ⁇ , ⁇ -transgene.
  • the level of ⁇ , ⁇ -transgene expression is conveniently at least 1/lOth that of mouse MHC class II and more conveniently the same.
  • transgenic non-human mammals of the invention have a number of uses including the study of any aspect of the immune system relating to MHC class II as well as drug and vaccine assays for example to determine the interaction of compounds with these cell surface proteins.
  • tissue can be removed and (i) cultured (eg. "Culture of Animal Cells - A Manual of Basic Technique” - R. Ian Freshney, A.R. Liss Inc.
  • MHC class II ⁇ , ⁇ -double transgenes include ⁇ , ⁇ -double transgenes of the DR class of sequences, especially of DR1; the Dw class of sequences, especially of Dw4, Dwl4.1 and Dw 14.2.
  • a particular ⁇ , ⁇ -double transgene is of DR4Dwl4.
  • a more particular transgene is the ⁇ , ⁇ -double transgene of human HLA-DR4Dw4.
  • Any convenient cell line may be used. These include those disclosed as above such as immortalised cell lines.
  • the cell line may be pluripotent and/or totipotent.
  • DR MHC class II gene products expressed by the transgenic non-human mammals of the present invention may interact with other factors to induce proliferation in human T cells.
  • a method for the identification of compounds which modulate the production or release of an immunologically active mediator comprises contacting a test compound with a polypeptide expressed by the ⁇ , ⁇ -double transgene of the invention and a factor which binds to the polypeptide to form a complex, which complex interacts with T cells and leads to the production or release of the immunologically active mediator, and detecting any modulation of production or release.
  • test compound may modulate the production or release of the immunologically active mediator by inhibiting binding of the polypeptide to the factor or any subsequent event.
  • Examples of convenient immunological events which may be used to detect any modulation of production or release of an immunologically active mediator include T cell proliferation, antibody production, and an inflammatory response.
  • test compound Any convenient test compound may be used.
  • antibodies such as monoclonal antibodies may be used to block the polypeptide expressed by the ⁇ , ⁇ -double transgene.
  • the factor is conveniently a peptide, conveniently a synthetic peptide.
  • a particular peptide for use in the above method in conjunction with the HLA-DR4Dw4 transgene is FHA- 07 _ 320 (Pro-Lys-Tyr-Val-Lys-Gln-Asn-Thr-Leu-Lys-Leu-Ala-Thr-Gly).
  • Figure 1 shows the construction of the DR ⁇ clone T9C.
  • the boxes represent exons of the DR ⁇ gene and the arrow indicates the direction of transcription.
  • 5'SS is the signal sequence
  • ⁇ l and ⁇ 2 are the extracellular domains.
  • TC are the transmembrane and cytoplasmic domains.
  • 3'UT is the 3' untranslated region, ⁇ l is an exon of the DR ⁇ gene.
  • Restriction maps for the EcoRI, BamHI and Sail restriction enzymes are also shown.
  • Figure 2 shows the generation of the DR ⁇ construct.
  • the boxes represent exons of the mouse IE ⁇ construct and the arrow indicates the direction of transcription.
  • L is the leader peptide.
  • 1 and 2 are the extracellular domains.
  • TC are the transmembrane and cytoplasmic domains.
  • 3'UT is the 3' untranslated region. Restriction sites for the BamHI and Xbal restriction enzymes are also shown.
  • the human DR ⁇ cDNA was cloned into the first exon of the mouse IE ⁇ gene, between the transcription initiation site and the translation start codon.
  • Figure 3(a) shows an autoradiograph of a Southern Blot including T9C DNA, liver DNA from non-transgenic mice, BSH DNA and DNA from the tails of transgenic and non-transgenic progeny hybridised to DR ⁇ cDNA.
  • Figure 3(b) shows an autoradiograph of a Southern Blot including WE32 ⁇ DNA, liver DNA from non-transgenic mice and DNA from transgenic and non-transgenic progeny hybridised to DR ⁇ cDNA.
  • Figure 4(a) shows an autoradiograph of a Northern Blot including RNA from liver, spleen, lung and kidney of DR ⁇ transgenic 1530 and RNA from BSH cell line hybridised to DR- ⁇ cDNA.
  • Figure 4(b) shows an autoradiograph of a Northern Blot including liver, lung, spleen and brain RNA from DR ⁇ transgenic 1499; liver, lung and heart RNA from DR ⁇ transgenic 1502, plus RNA from BSM cell line hybridised to DR ⁇ oligonucleotide.
  • Figure 5 shows the FACS profiles of blood cells from a mouse containing HLA-DR4Dw4 and transgenes stained with antibodies directed towards HLA-DR (MAb L243) and mouse MHC Class II protein (MAb 10-3.6.2
  • Figure 6 shows two FACS histograms of spleen cells stained with MAb L234 plus phycoerythrin-conjugated goat anti-maouse IgG (Fc)FITC followed by FITC-conjugated rat-anti-IA (Serotec clone) or FITC-conjugated rat-anti-Thy-1 (Serotec clone) MAbs.
  • the expressing I-A molecules also express HLA-DR4DW4 molecules (population B of Figure 6a) , while the HL -DR4Dw4-negative cells also do not express I-A molecules.
  • mouse T cells CD3-positive spleen cells
  • mouse MHC Class II Molecules also do not express HLA-DR4Dw4 molecules (Population B of Figure 6b) .
  • Figure 7 shows the responses of LN T cells obtained from 10 individual mice (5 HLA-DR4Dw4-transgenic mice; 5 non-transgenic littermates) immunised with FHA307-320. It can be seen that addition of FHA307-320 to primed LN T cells from HLA-DR4Dw4-transgenic mice produces a dose-dependent proliferative response, whereas primed LN T cells from non-transgenic littermates do not proliferate when FHA307-320 is added.
  • FIG 8 shows the effect of anti-HLA-DR monoclonal antibodies on recognition of FHA307-320 by primed T cells from HLA-DR4Dw4-transgenic mice.
  • Spleen cells and primed LN T cells were prepared as described for Example 4, and a stimulatory concentration of FHA307-320 (10 ⁇ M) was added.
  • Monoclonal antibody L243 which binds HLA-DR4Dw4 molecules, but not mouse MHC Class II molecules were also added, and the cultures incubated, harvested and counted as described. It can be seen that addition of MAb L243 completely inhibits prolifereation of primed LN T cells from transgenic mice.
  • a control monoclonal antibody (MKD6) which would not react with HLA-DR4Dw4 molecules has no inhibitory activity, showing that the effect is specific to HLA-DR4Dw4.
  • FIG. 9 shows that HLA-DR4Dw4 transgenic mice produce recall delayed type hypersensitity responses to the HLA-DR4Dw4-binding peptide FHA307-320. It can be seen that administration of an HLA-DR4Dw4-binding antagonist peptide to HLA-DR4Dw4 transgenic mice results in measurable inhibition of the delayed type hypersensitivity response. In contrast, an antagonist of mouse MHC Class II molecules (SNase61-80) demonstrated no inhibitory activity. These results confirm that the rsponse is HLA-DR4Dw4 restricted, and that this method can be used to detect HLA-DR4 antagonist peptides.
  • a cosraid clone, T9C, containing the vhole of the human DR4 ⁇ gene vas provided by T. Spies (Spies et al., Proc. Natl. Acad. Sci. USA 82:5165 1985).
  • a 22Kb BamHI to Sail fragment containing the 7Kb gene and 5' and 3' flanking sequence vas generated from T9C Figure 1 and isolated from agarose gels for icroinjection (cf. Hogan et al., Manipulating the mouse embryo - A laboratory manual, Cold Spring Harbour Laboratory Press, 1986) at a concentration of 2ng/ ⁇ l.
  • Human DR4Dv4 ⁇ chain cDNA vas amplified from a human ⁇ -lymphoblastoid cell line (BSH - a transformed Epstein-Barr virus obtained from R. Bolhuis, ETNO, Rijsvijk, NL).
  • BSH human ⁇ -lymphoblastoid cell line
  • the cDNA vas then used in a PCR reaction with oligonucleotides 238 (GTCGAATTCTCCAGCATGGTGTGTCTGAAG) and
  • TCTAGATTAA thus generating a Bglll site.
  • the construct comprising the DR ⁇ cDNA, SV40 splice site and poly A recognition sequence vas purified on a Bglll to BamHI fragment and susequently subcloned into the BamHI site of plasmid p ⁇ E32 provided by D. Hathis, Stanford University (Dorn et al, Proc. Natl. Acad. Sci.USA, 1987, 84, 6249-6253).
  • pWE32 contains the mouse IE ⁇ gene modified, for clonine purposes, by removal of a BamHI site from the first intron and introduction of a BamHI site in the untranslated region of the first exon.
  • the IE ⁇ regulatory sequences and gene now including the DR ⁇ cDNA in the first exon were isolated by Bglll digestion.
  • the 9.4 Kb fragment was then gel purified and resuspended at 2ng/ ⁇ l in TE (0.5 mM Tris - pH 7.5, 0.1 mM EDTA) for microinjection.
  • CBA-Ca x C57B1/6 (Fl) female mice (ZENECA - Alderley Park) were superovulated and mated with Fl males. Fertilzed oocytes were microinjected with either the 22Kb BamHI - Sail fragment containing the DR ⁇ gene, or the 9.4 Kb Bgll fragment containing the DR ⁇ gene and incubated overnight. Viable embryos were transferred to the oviducts of pseudopregnant Fl females (mated with vasectomised males) and allowed to develop to term.
  • the resulting progeny were analysed to determine whether the transgene was present. Approximately 0.5cm of tail was obtained from each animal, sliced with a scalpel blade, and digested overnight at 55°C in 0.5 ml lysis buffer (100 m Tris.HCl pH 8.5, 5mM EDTA, 0.2% SDS, 200 mM NaCl, 100 ⁇ g Pr ⁇ teinase K/ml. The solution was extracted with phenol/chloroform and DNA was precipatated. DNA was precipitated with an equal volume of isopropanol, washed in 70% ethanol and resuspended in 500 ⁇ l TE (0.1M Tris pH8, 0.01M EDTA) at 55°C.
  • 0.5 ml lysis buffer 100 m Tris.HCl pH 8.5, 5mM EDTA, 0.2% SDS, 200 mM NaCl, 100 ⁇ g Pr ⁇ teinase K/ml.
  • the solution was extracted with phenol/
  • PCR analysis using DR ⁇ or DR ⁇ specific primers was used to identify transgenic animals. Approximately 100 ng of tail DNA were used in PCR reactions with Taq polymerase (Cetus - Amplitaq) using conditions described by the manufacturer (Perkin-Elmer Cetus) on a Techne thermal cycling machine. The amplimers used were: DR ⁇ 5'AAGAACATGTGATCATCCAGGCC (EXON), 5' CCCCAGTGCTTGAGAAGAGGCTCA (EXON 2) at 92°C for 2 min, 65°C for 2 min and 72°C for 2 min for 35 cycles giving a 1018 bp product.
  • DNA (10 ⁇ G) was transferred to Hybond membrane (Amersham) using 20 x SSC (3M NaCl, 0.3 M tri-sodium citrate - Na C H 0 .2H O) , UV fixed, prehybridised and hybridised 3 6 5 7 2 according to the manufacturers recommendations with a P labelled probe of either the DR ⁇ or DR ⁇ cDNA using standard protocols. The results are shown in Figures 3 and 4.
  • DR 08 was chosen to establish a transgenic line and further reference to DR ⁇ relates to DR ⁇ 08. Microinjection of the DR ⁇ construct resulted in 3 'founders', ⁇ 325, ⁇ 380 and ⁇ 356. ⁇ 325 and ⁇ 380 did not transmit the transgene to their progeny. A line was therefore established from mouse/human hydrid ⁇ 356 and further reference to DR ⁇ relates to this line.
  • FISH Fluorescent in situ hybridisation
  • FISH fluorescent in situ hybridisation
  • labelled DNA 100 ng was dissolved in 25 ⁇ l of hydridisation mix (10% dextran sulphate, 50% formamide, 2xSSC, 0.1 mM EDTA, 0.05mM Tris pH7.5, 100 ⁇ g/ml denatured salmon sperm DNA) and denatured at 80°C for 10 minutes. Denatured probe was hybridised to the slides under a coverslip at 37°C for 48 hours. Slides were washed 3x5 minutes in 50% formamide/2xSSC pH7.0, at 42°C and 3x5 minutes in 2xSSC at 42°C and blocked for 60 minutes with 5% non-fat dried milk (Marvel - Premier Brands UK Ltd) in 4xSSC, 0.05% Triton X 100.
  • hydridisation mix 10% dextran sulphate, 50% formamide, 2xSSC, 0.1 mM EDTA, 0.05mM Tris pH7.5, 100 ⁇ g/ml denatured salmon sperm DNA
  • Detection was by sequential incubation in fluoresicein isothiocyanate (FITC - Vector Laboratories) - avidin (DCS - D cell sorter grade) followed biotinylated anit-avidin (Vector Laboratories) , both at 5 ⁇ g/ml in 4xSSC pH7.0, 0.05% Triton-x 100, 3%BSA, at 37°C for 20 minutes with 3x3 minute washed in 4XSSC/0.05% TRigton between each layer. After 304 layers of avidin, slides were washed in phosphate buffered saline (lxPBS -0.137 mM NaCL, 2.7mM KC1, 8.1 mM Na HPO .2H O,
  • DABCO 1,4-diazobicyclo- [2.2.2]octane
  • DRo.08 transgenic animals were mated .with DRE356 animals to generate progeny carrying both transgenes.
  • Blood from an incision in the tail was drawn into a lOO ⁇ l heparinised tube (BDH), and immediately blown out into 1ml of ice cold PBS.
  • the sample was then centrifuged (2000rpm for 5 minutes), the pellet resuspended in 200 ⁇ l of ice cold PBS containing 20Z normal rabbit serum plus 0.2Z sodium azide, and 50 ⁇ l portions pipetted into LP4 tubes (Luckham). After 15 minutes incubation in a refrigerator, 50 ⁇ l of pre-titrated monoclonal antibody-containing supernatant diluted (typically 1:5) in PBS + 20% normal rabbit serum + 0.2Z sodium azide was added to the cell suspension.
  • the cells were washed by addition of 450 ⁇ l of cold PBS + 2% foetal calf serum (FCS) + 0.21 sodium azide followed by centrifugation (2000rpm for 5 minutes) at 4°C. The supernatant was then decanted by suction, and the pellet resuspended by vortexing for 2-3 seconds.
  • 50 ⁇ l of FITC-conjugated Goat anti-mouse IgG F(c) antibody (Serotec) preabsorbed for 30 minutes with 502 mouse spleen cell suspension
  • diluted 1:75 in PBS + 20% rabbit serum + 0.21 sodium azide was added, and the pellet resuspended by vortexing.
  • Figure 5 shows the FACS profiles of blood cells from a mouse containing HLA-DR4Dw4 and transgenes stained with antibodies directed towards HLA-DR (MAb L243 - ATCC HB55) and mouse MHC Class II protein (MAb 10-3.6.2 - ATCC TIB92). It can be seen that similar numbers of cells from HLA-DR4Dw4 transgenic mice are stained with antibodies to mouse and human MHC Class II proteins, respectively.
  • Spleens were excised from transgenic mice, placed in a 50mm diameter sterile plastic petri dish containing 3 ml of cold sterile PBS, and cut into small (approx 3mm) pieces. The pieces were squashed using the plunger of a 2ml plastic syringe (Asik) to release the spleen cells, and a further 7ml of ice cold PBS were added using a 10ml pipette. The suspension was pipetted up and down vigorously ten times, and the mixture filtered through a Cell Strainer (Becton Dickinson) into a 25ml sterile glass beaker to remove debris.
  • a Cell Strainer Becton Dickinson
  • the cell suspension was poured into a 15ml sterile plastic conical tube (Falcon), and centrifuged at room temperature (1400rpm for 5 mins). The cell pellet was then resuspended in 3ml PBS, and 2ml of Lympholyte M (Jackson Labs) layered underneath. The cells were centrifuged at 2000rpm for 15 mins at room temperature, and the cells at the interface representing the mononuclear population were then collected and diluted into 10ml ice cold PBS in a 15ml conical tube. The cells were washed twice in PBS before being counted.
  • Falcon sterile plastic conical tube
  • cells were resuspended (10-20x10 /ml) in PBS + 20% rabbit serum + 0.2% sodium azide, and processed as disclosed in Example 2, except that the treatment with FACS Lysis Buffer was omitted.
  • spleen mononuclear cells express HLA-DR molecules and mouse I-A molecules.
  • spleen cells were stained with MAb L243 plus phycoerythrin-conjugated goat anti-mouse IgG (Fc) followed by FITC-conjugated rat-anti-I-A (Serotec clone MCA 46F) or FITC-conjugated rat-anti-CD3 (Serotec MCA 500F) MAbs.
  • the two colour FACS histograms show that the spleen cells expressing I-A molecules also express HLA-DR4Dw4 molecules (population B of Figure 6a), while the HLA-DR4Dw4-negative cells also do not express I-A molecules. Furthermore, mouse T cells (CD3-positive spleen cells) which do not express mouse MHC Class II molecules, also do not express HLA-DR4Dw4 molecules (Population A of Figure 6b).
  • the pattern of expression of the HLA-DR4Dw4 transgenes in lymphoid cells of the spleen is similar to that of endogenous MHC Class II products.
  • mice were immunised with lOnmol of peptide FHA307-320 (Sequence : Pro-Lys-Tyr-Val-Lys-Gln-Asn-Thr-Leu-Lys-Leu-Ala-Thr-Gly) mixed 1:1 in Complete Freund's Adjuvant (Difco Labs). 0.1ml of the mixture was administered sub-cutaneously in a single site in the flank using a 1ml plastic syringe and 23 gauge needle. Mice were sacrificed 7-10 days following immunisation with peptide, and the enlarged draining ingunal lymph node, and spleen were dissected from each mouse.
  • Lymph node (LN) cell suspensions were prepared by passing through a cell strainer as disclosed for spleen cells in Example 3. The final suspension was suspended in 1ml of warm tissue culture medium (RPMI-1640, Gibco) supplemented with 5% heat inactivated FCS + 2mM glutamine + lOOU/ml penicillin/lOOg/ml streptomycin + 50 ⁇ M 2-mercaptoethanol (hereinafter referred to as "culture medium”), and the suspension was then applied to a nylon wool column.
  • the nylon wool column was prepared by adding 0.6g nylon wool to the barrel of a 10ml plastic syringe, and the column autoclaved.
  • the sterile column is washed through with 20ml of warm culture medium approx 1 hour before use, and incubated at 37°C until cells are added.
  • the LN cell suspension was added to the top of the column dropwise, and incubated for 45 mins in a CO- incubator at 37°C.
  • Non-adherent cells were then eluted by adding 20ml of warm culture medium dropwise, and collecting the flow-through into a sterile 30ml plastic universal container.
  • the resulting cells (“LN T cells”) were pelleted, resuspended in 1ml of warm culture medium, counted, and further adjusted to a density of 4xl0 6 /ml.
  • Spleen mononuclear cell suspensions were prepared as described in Example 3.
  • spleen cells were treated with anti-Thy-1 plus complement to deplete T cells.
  • spleen mononuclear cells were suspended (5x10 /ml) in culture medium containing a 1:10,000 dilution of anti-Thy-1 MAb (Serotec) for 30 minutes, washed once in cold PBS, and resuspended (5x10 /ml) in Low-tox rabbit complement (Serotec) for 45 minutes at 37°C.
  • the cells were washed twice with warm culture medium, resuspended in 2ml warm culture medium, counted, and adjusted to a density of 4x10 /ml.
  • LN T cells 50 ⁇ l/well and spleen cells (50 ⁇ l/well) are added to lOO ⁇ l of medium containing peptides (eg. FHA307-320) at the indicated concentrations in 96-well microtitre plates (Nunc), and incubated for 4 days at 37°C in a humidified atmosphere of 5% CO. in air.
  • Responding T cells are quantified by addingAlCi/ml 3H-thymidine (Amersham) for 6 hours, and the plates harvested and counted on a Beta-plate counter (LKB). Results are expressed as the mean (+SEM) of triplicate cultures.
  • Peptide FHA307-320 is known to bind to HLA-DR4Dw4 and induce proliferation in primed human T cells of appropriate specificity.
  • Figure 7 shows the responses of LN T cells obtained from 10 individual mice (5 HLA-DR4Dw4-transgenic mice; 5 non-transgenic littermates) immunised with FHA307-320. It can be seen that addition of FHA307-320 to primed LN T cells from HLA-DR4Dw4-transgenic mice produces a dose-dependent proliferative response, whereas primed LN T cells from non-transgenic littermates do not proliferate when FHA307-320 is added.
  • Honoclonal antibody L243 which binds HLA-DR4Dw4 molecules, but not mouse MHC Class II molecules vas also added, and the cultures incubated, harvested and counted as described above. The results are shown in Figure 8, from which it can be seen that addition of MAb L243 completely inhibits proliferation of primed LN T cells from transgenic mice. In contrast, a control monoclonal antibody (MKD6 - ATCC HB3) which would not react with HLA-DR4Dw4 molecules has no inhibitory activity, showing that the effect is specific to HLA-DR4Dw4.
  • Primed LN T cells were prepared as described for Example 4.
  • spleen cells were prepared as for Example 4, and "fixed" with gluteraldehyde prior to addition of peptides. Specifically, anti-Thy-1 plus complement-treated spleen mononuclear cells (as prepared in Example 4 above) were washed in PBS, and resuspended at 5x10 cells/ml for 30 seconds in 0.5% gluteraldehyde. An equal volume of 0.4 mM lysine in PBS is added for 3 minutes, and the cells pelleted and washed twice in culture medium.
  • the fixed cells were resuspended to 4x10 /ml in serum-free tissue culture medium (RPMI-1640 medium, Gibco), and lOO ⁇ l added to lOO ⁇ l of serum-free RPMI1640 medium containing l ⁇ M FHA307-320 and blocking peptides at concentrations between 0.1-100 ⁇ M in 96-well microtitre culture plates. After 2 hours incubation, the cells were pelleted, the medium removed by suction, and 200 ⁇ l of culture medium added. The cells were again pelleted, the medium removed, and a further 200 ⁇ l of medium added. After pelleting the cells and removing the medium once more, 2x10 primed LN T cells were added in 200 ⁇ l of warm culture medium. Cultures are then treated as described in Example 4.
  • HLA-DR4Dw4-binding peptides are able to inhibit the presentation of FHA307-320 to primed LN T cells from transgenic mice.
  • peptides able to compete for binding to mouse MHC Class II molecules I-Ak ; I-Ek
  • I-Ak mouse MHC Class II molecules
  • I-Ek mouse MHC Class II molecules
  • HLA-DR4Dw4-transgenic mice essentially according to the method of Adorini et al (1988; Nature 334:623).
  • Transgenic mice are immunised with a mixture of 10 nmoles of FHA307-320 mixed with an effective amount (eg 1-500 nmoles) of the antagonist peptide in 1001 of a 1:1 mixture of Freund's Complete Adjuvant and PBS. After 7-14 days, mice are killed, and spleen and LN T cell suspensions made and assayed for reactivity to 1M FHA307-320 as described in Example 4.
  • HLA-DR4Dw4 antagonist peptides are able to inhibit the priming of LN T cells in transgenic mice, demonstrating that they are able to antagonise the function of HLA-DR4Dw4 in vivo.
  • HLA-DR transgenic mice are immunised with a mixture of an effective amout of FHA307-320 (100 ng in this example) in 109 mictrolitres of a 1:1 mixture of Freund's Complete adjuvant and PBS. After 7-14 days, approximately 30 microlitrues of a 100 micromolar solution of FHA307-320 is injected sub-plantar into one hind foofpad, and the resultant immune response determined by measuring foot swelling wit hmicronic calipers.
  • HLA-DR4Dw4-binding peptides administered either by admixing with the sub-plantar challenge injection, or given by other standard route, or by slow-release depots such as osmotic mini-pumps can be shown to inhibit the swelling induced by FHA307-320, showing that they are able to antagonise the function of HLA-DR4Dw4 in vivo ( Figure 8) .

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Environmental Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PCT/GB1994/001582 1993-07-23 1994-07-22 Human mhc class ii double transgene and uses WO1995003331A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP7505017A JPH09501315A (ja) 1993-07-23 1994-07-22 ヒトｍｈｃ▲ｉｉ▼群二重トランスジーンおよび用途
AU72314/94A AU7231494A (en) 1993-07-23 1994-07-22 Human mhc class ii double transgene and uses
EP94921706A EP0710250A1 (en) 1993-07-23 1994-07-22 Human mhc class ii double transgene and uses

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB939315303A GB9315303D0 (en) 1993-07-23 1993-07-23 Polypeptide
GB9315303.9 1993-07-23

Publications (1)

Publication Number Publication Date
WO1995003331A1 true WO1995003331A1 (en) 1995-02-02

Family

ID=10739326

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1994/001582 WO1995003331A1 (en) 1993-07-23 1994-07-22 Human mhc class ii double transgene and uses

Country Status (5)

Country Link
EP (1) EP0710250A1 (ja)
JP (1) JPH09501315A (ja)
AU (1) AU7231494A (ja)
GB (2) GB9315303D0 (ja)
WO (1) WO1995003331A1 (ja)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997026538A1 (en) * 1996-01-19 1997-07-24 Virginia Mason Research Center Allele-specific peptide epitope strategy for vaccine development
WO1998035989A1 (en) * 1997-02-14 1998-08-20 Toernell Jan Method for screening and transgenic model
WO2002010190A3 (en) * 2000-07-29 2002-05-02 Genaissance Pharmaceuticals Haplotypes of the il12b gene
US8847005B2 (en) 2011-10-28 2014-09-30 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex mice
US9043996B2 (en) 2011-10-28 2015-06-02 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex animals
US9591835B2 (en) 2011-10-28 2017-03-14 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex animals
US9615550B2 (en) 2011-10-28 2017-04-11 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex mice
US9848587B2 (en) 2013-02-20 2017-12-26 Regeneron Pharmaceuticals, Inc. Humanized T cell co-receptor mice
US10154658B2 (en) 2013-02-22 2018-12-18 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex mice
US10314296B2 (en) 2013-02-22 2019-06-11 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex mice
US11259510B2 (en) 2015-04-06 2022-03-01 Regeneron Pharmaceuticals, Inc. Humanized T cell mediated immune responses in non-human animals

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998002577A1 (en) * 1996-07-15 1998-01-22 The Children's Medical Center Corporation Method to co-detect introduced genes and their products
CN1333239A (zh) * 2000-07-07 2002-01-30 上海博德基因开发有限公司 一种新的多肽——人ⅲ型主要组织相容性蛋白复合物61和编码这种多肽的多核苷酸

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992007070A1 (en) * 1990-10-23 1992-04-30 Board Of Regents, The University Of Texas System Transgenic rats and animal models of inflammatory disease
WO1993005817A1 (en) * 1991-09-19 1993-04-01 President And Fellows Of Harvard College Transgenic mhc class i and class ii antigen-deficient mammals

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5583031A (en) * 1992-02-06 1996-12-10 President And Fellows Of Harvard College Empty major histocompatibility class II heterodimers

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992007070A1 (en) * 1990-10-23 1992-04-30 Board Of Regents, The University Of Texas System Transgenic rats and animal models of inflammatory disease
WO1993005817A1 (en) * 1991-09-19 1993-04-01 President And Fellows Of Harvard College Transgenic mhc class i and class ii antigen-deficient mammals

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BUELOW, R. ER AL.;: "Comparison of three different forms of HLA-DR4DW4 proteins", EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 23, no. 1, January 1993 (1993-01-01), VCH VERLAGSGESELLSCHAFT, DEUTSCHLAND, pages 69 - 76 *

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997026538A1 (en) * 1996-01-19 1997-07-24 Virginia Mason Research Center Allele-specific peptide epitope strategy for vaccine development
WO1998035989A1 (en) * 1997-02-14 1998-08-20 Toernell Jan Method for screening and transgenic model
WO2002010190A3 (en) * 2000-07-29 2002-05-02 Genaissance Pharmaceuticals Haplotypes of the il12b gene
US10045516B2 (en) 2011-10-28 2018-08-14 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex animals
US10219493B2 (en) 2011-10-28 2019-03-05 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex mice
US9585373B2 (en) 2011-10-28 2017-03-07 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex mice
US9591835B2 (en) 2011-10-28 2017-03-14 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex animals
US9615550B2 (en) 2011-10-28 2017-04-11 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex mice
US9700025B2 (en) 2011-10-28 2017-07-11 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex animals
US11219195B2 (en) 2011-10-28 2022-01-11 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex mice
US8847005B2 (en) 2011-10-28 2014-09-30 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex mice
US10986822B2 (en) 2011-10-28 2021-04-27 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex mice
US9043996B2 (en) 2011-10-28 2015-06-02 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex animals
US10869466B2 (en) 2011-10-28 2020-12-22 Regeneran Pharmaceuticals, Inc. Genetically modified major histocompatibility complex mice
US10779520B2 (en) 2011-10-28 2020-09-22 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex animals
US10820581B2 (en) 2013-02-20 2020-11-03 Regeneron Pharmaceuticals, Inc. Humanized T cell co-receptor mice
US9848587B2 (en) 2013-02-20 2017-12-26 Regeneron Pharmaceuticals, Inc. Humanized T cell co-receptor mice
US10314296B2 (en) 2013-02-22 2019-06-11 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex mice
US10154658B2 (en) 2013-02-22 2018-12-18 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex mice
US11224208B2 (en) 2013-02-22 2022-01-18 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex mice
US11259510B2 (en) 2015-04-06 2022-03-01 Regeneron Pharmaceuticals, Inc. Humanized T cell mediated immune responses in non-human animals

Also Published As

Publication number Publication date
AU7231494A (en) 1995-02-20
GB9414833D0 (en) 1994-09-14
GB2280186A (en) 1995-01-25
GB9315303D0 (en) 1993-09-08
JPH09501315A (ja) 1997-02-10
EP0710250A1 (en) 1996-05-08

Similar Documents

Publication Publication Date Title
US5434340A (en) Transgenic mice depleted in mature T-cells and methods for making transgenic mice
Umanoff et al. The murine N-ras gene is not essential for growth and development.
Strauss et al. Germ line transmission of a yeast artificial chromosome spanning the murine α1 (I) collagen locus
Tybulewicz et al. Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto-oncogene
US5616491A (en) Knockout mice
EP0710250A1 (en) Human mhc class ii double transgene and uses
EP0700435A1 (en) Transgenic mammals lacking expression of particular cd45 isoforms
US6482937B1 (en) Porcine Oct-4 promoter
CA2153806C (en) Detection and treatment of mutations in a cd40 ligand gene
AU712016B2 (en) Ikaros transgenic cells and animals
US7449562B2 (en) PERV screening method and use thereof
KR100607527B1 (ko) 인간이 아닌 형질전이된 동물로부터의 고 전사 복합체의 정제방법
CA2311166C (en) Nucleic acids involved in the responder phenotype and applications thereof
US20020104112A1 (en) Ikaros regulatory elements and uses thereof
WO1998046726A1 (en) A-myb NULL MUTANT TRANSGENIC ANIMALS AND USES THEREOF
Strominger Chromosome Spanning the Murine a,(l)
JPH11196709A (ja) Ｄｏｃ２α遺伝子が欠損したトランスジェニック・マウス
JP2003116407A (ja) ラディキシンノックアウト動物

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB GE HU JP KE KG KP KR KZ LK LU LV MD MG MN MW NL NO NZ PL PT RO RU SD SE SI SK TJ TT UA US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1994921706

Country of ref document: EP

ENP Entry into the national phase

Ref country code: US

Ref document number: 1996 586674

Date of ref document: 19960123

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 1994921706

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1994921706

Country of ref document: EP